Decentralized Trials and Telemedicine Research Accelerated During COVID-19 Pandemic
While the first sign of the pandemic in many industries was an increase in activity, in the world of R&D jobs in pharma it was when nothing happened at all. The usual supply of clinical data simply disappeared as lockdowns forced people to stay at home and made normal structures and circumstances impossible. 40% of life sciences companies had to delay or cancel a study as a result of the conditions that were triggered by the pandemic and this has...
View full press release